Navigation Links
The hot -- and cold -- interventional radiology treatments for recurrent prostate cancer

TAMPA, Fla. (March 16, 2010)The first known patient cases using magnetic resonance-guided heat (laser interstitial thermal therapy) or cold (cryoablation) to treat prostate cancer recurrence after surgical removal of the prostate gland were presented by physicians at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa. Many of these patients have also failed salvage radiation treatment and are often presented with limited therapeutic options. MR-guided focal therapy offers a new treatment choice for patients because of the improved detection of early prostate cancer recurrences best seen with MR imaging.

"Magnetic resonance-guided ablation may prove to be a promising new treatment for prostate cancer recurrences; it tailors treatment modality (imaging) and duration to lesion size and location and provides a less invasive and minimally traumatic alternative for men," said David A. Woodrum, M.D., Ph.D., an interventional radiologist at the Mayo Clinic in Rochester, Minn. "The safe completion of four clinical cases using MR-guided ablation therapy to treat prostate cancer in patients who had failed surgery demonstrates this technology's potential," he said, stressing, however, that the application for using ablation therapy in treating prostate cancer is relatively new. In the studya major collaboration of physicians from Mayo Clinic radiology and urology departmentsthe four patients with recurrent prostate cancer had previously been treated with radical prostatectomy, an operation to remove the entire prostate gland and adjacent structures. The men underwent salvage therapy treated with either MR-guided laser interstitial thermal therapy, which uses high temperatures generated by local absorption of laser energy, or cryoablation, generating freezing with extremely cold gas destroying cancerous tissue. By using MR imaging with temperature mapping and/or ice ball growth monitoring, clinicians tailored treatments to lesion size and location. "Immediately after treatment, we found no definite residual tumor. The treatment preserved the patients' baseline sexual and urinary function and had no major complications," added Woodrum.

Prostate cancer is the third most common cause of death from cancer in men and accounted for 27,360 deaths last year. Most of the 192,280 men diagnosed with cancer of the prostate (adenocarcinoma) in 2009 were older than 50 years of age. Prostate cancer management decisions often depend on the degree of spread or stage of the cancer. Treatment alternatives may include surgery, radiation therapy, cryosurgery, chemotherapy, active surveillance or manipulation of hormones that affect the cancer. Cancer recurrence rates after surgical resection can be as high as 15󈞀 percent, leaving a significant number of men who require salvage therapy with radiation therapy or hormones; however, each has drawbacks. Some men continue to have detectable residual prostate cancer even after surgical removal and radiation treatment; for these individuals this potential new therapy with imaging guidance presents an innovative method to target and treat the cancer when all others have failed.

In this retrospective review, each of the four men was found to have post surgical recurrent prostate cancer detected by MR imaging. Two were treated with MR-guided laser interstitial thermal therapy; the other two were treated with cryoablation. Biopsy-proven cancer lesions ranged in size from 6󈝽 millimeters and were located in the prostate bed just inferior to the bladder and anterior to the rectum, where the prostate gland had previously resided. The men had no detectable metastases at the time of treatment. For both ablation methods, two to three probes or applicators were used in each case. Intermittent MR imaging was employed during the procedures for placement of the probes/applicators and to actively monitor ablation size during treatment to completely cover the lesion.

While stressing that this treatment was in the formative stages, additional work is needed to see which patients will be best suited for the ablation procedure and to examine middle- and long-term results for efficacy, noted Lance A. Mynderse, M.D., a Mayo Clinic urologist.


Contact: Maryann Verrillo
Society of Interventional Radiology

Related biology technology :

1. Going for gold with a novel interventional radiology treatment for pancreatic cancer
2. LUMEDX Launches New Interventional Radiology Software
3. Terumo Interventional Systems Launches a Complete Line of Coronary Diagnostic Catheters
4. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
5. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
6. Interventional Cardiologists Nico Pijls, Bernard De Bruyne to Discuss Benefits of Measuring Coronary Pressure in Improving Multivessel PCI at ESC Congress 2007
7. Visage Imaging to Provide Visage(R) CS Enterprise Wide Advanced Visualization Solutions to Advanced Radiology Consultants
8. St. Paul Radiology Selects AMICAS
9. Diagnostic Imaging - Enters Purchase Agreement to Acquire Teleradiology Company
10. Arcadia Radiology Medical Group Chooses AMICAS
11. MedQuist and StructuRad Form Partnership to Integrate Report Macros into SpeechQ for Radiology(TM)
Post Your Comments:
(Date:10/13/2015)... Oct. 13, 2015 PharmaCyte Biotech, Inc. (OTCQB: PMCB) ... volume was at near average with 1,308,352 shares being traded. ... this year hitting a low of $.072 in September, then ... --> Our due diligence will show investors in ... Get our report by using the link below at no ...
(Date:10/13/2015)... ... October 13, 2015 , ... InSphero AG , the ... cell culture models, has launched a 14 Day Hepatotoxicity Testing Service ... Human Liver Microtissues. The service streamlines toxicity testing of compounds in InSphero’s ...
(Date:10/13/2015)... DE (PRWEB) , ... October 13, 2015 , ... ... its new President. Steve joins as the Pistoia Alliance continues to drive to ... , The non-profit Pistoia Alliance is focusing its vision and expanding its work ...
(Date:10/13/2015)... , Oct. 13 2015 Research and ... "US & Europe Markets for Bone Morphogenetic Protein ... to their offering. --> ... that induce the formation of bone after a fracture. ... embryonic development in the formation of the skeleton. There ...
Breaking Biology Technology:
(Date:10/13/2015)... , Oct. 13, 2015 Feedzai ... learning to analyze big data and minimize risk in ... Emailage , an innovative fraud prevention solution that ... risk based on a user,s email address. The two ... learning solution that combines email risk assessment with fraud ...
(Date:10/13/2015)... , October 13, 2015 Dragon ... tech companies in China , announced today ... Limited ("Yazheng"), has received a contract for Multi-Format Naked Eye ... awarded Yazheng approximately $450,000 for the project that is expected ... achieve 30% to 35% in gross profits. ...
(Date:10/13/2015)... , Oct. 7, 2015 Research and ... the "India Biometrics Authentication & Identification Market - ... --> --> ... $823.46 million in 2014 to $2.06 billion in 2020 ... 2020. India . Growing ...
Breaking Biology News(10 mins):